Skip to main content
ORGANOIDSCIENCES LTD. logo

ORGANOIDSCIENCES LTD. — Investor Relations & Filings

Ticker · 476040 ISIN · KR7476040001 KO Professional, scientific and technical activities
Open in API
Filings indexed 53 across all filing types
Latest filing 2025-03-28 Audit Report / Informat…
Country KR South Korea
Listing KO 476040

About ORGANOIDSCIENCES LTD.

https://organoidrx.com/en/

ORGANOIDSCIENCES LTD. is a biotechnology company specializing in organoid-based technologies for drug development and regenerative medicine. The company develops next-generation cell therapies and treatments for incurable diseases by creating three-dimensional cell cultures that replicate the structure and function of human organs. Its core offerings include an Organoid-Based Regenerative Therapeutics Platform to overcome the limitations of conventional therapies and an evaluation platform for assessing drug efficacy and toxicity, providing an alternative to animal models. Additionally, the company has developed the Polaris Platform for evaluating immunotherapy sensitivity. ORGANOIDSCIENCES aims to provide innovative solutions for precise and proactive care, shifting the paradigm in the therapeutics market.

Recent filings

Filing Released Lang Actions
감사보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Organoid Sciences Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's opinion from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a simple announcement. FY 2024
2025-03-28 Korean
연결감사보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Organoid Sciences Co., Ltd. It includes the independent auditor's report from Samil PricewaterhouseCoopers, along with the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows) and detailed notes for the fiscal year ending December 31, 2024. Since it contains the full audited financial statements and is not merely an announcement or a summary, it is classified as an Annual Report (10-K equivalent in this context). FY 2024
2025-03-28 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고서) filed by Organoid Science Co., Ltd. It details changes to the public offering schedule, subscription dates, and related risk factors for a stock issuance. In the context of financial filings, a Securities Registration Statement is a primary regulatory document for capital raising. Since it is a formal regulatory filing regarding the issuance of shares, it falls under the 'Regulatory Filings' category as the most appropriate classification for this type of document in the provided schema.
2025-03-20 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by Organoid Sciences Co., Ltd. It is a formal regulatory filing submitted to the financial authorities (likely the Financial Supervisory Service in South Korea) to register securities for public offering. The text explicitly mentions it is a 'Correction Report' (정정신고) for a previously submitted registration statement. This type of document is a standard regulatory filing for capital raising and does not fit into specific categories like '10-K' (Annual Report) or 'ER' (Earnings Release). Therefore, it is classified as a Regulatory Filing.
2025-02-17 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details the company's (Organoid Sciences Co., Ltd.) intent to offer securities (common shares), provides investment risk factors, and outlines the business and financial status for potential investors. This is a formal regulatory filing for a public offering, which falls under the category of Regulatory Filings (RNS) as it is a primary document for securities registration.
2025-01-17 Korean
감사보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Organoid Sciences Co., Ltd. for the fiscal year ending December 31, 2023. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is a comprehensive financial audit document, not an announcement or a summary, and fits the definition of an Audit Report (AR). FY 2023
2024-03-29 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.